|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table S1. The patients for the expression analyses in PB.** | | | | | |
| no | drug | subtype | site of relapse | pretreatment drugs  after relapse | style of disease progression |
| 1 | S-1 | ER+HER2- | bone | PTXb+BV c | - |
| 2 | S-1 | ER+HER2- | lung, bone | HRd | - |
| 3 | S-1 | ER+HER2- | liver, bone, lymph nodes | - | NMg+PEMh |
| 4 | S-1 | ER+HER2- | lung, bone | HR、PTX+BV、HR | - |
| 5 | S-1 | TNa | liver, bone | - | NM+PEM |
| 6 | S-1 | ER+HER2- | liver, bone, lymph nodes | HR | - |
| 7 | S-1 | TN | lymph nodes | - | PEM |
| 8 | S-1 | ER+HER2- | liver, bone, lymph nodes | HR | NM |
| 9 | Eribulin | TN | lung | Cape e | PEM |
| 10 | Eribulin | TN, ER+HER2- | pleura, lymph nodes | PTX+BV、S-1 | NM+PEM |
| 11 | Eribulin | ER+HER2- | lymph nodes | HR、PTX+BV、VNBf | PEM |
| 12 | Eribulin | ER+HER2- | lung | PTX+BV | - |
| aTN, Triple negative bPTX, Paclitaxel cBV, Bevacizumab dHR, Hormone eCape, Capecitabine fVNB, Vinorelbine gNM, new metastasis hPEM, pre-existing metastasis | | | | | |
|  |  |  |  |  |  |